Glucose-Responsive Insulin Analogues with Diol and Binding Element
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin therapies for diabetes mellitus face challenges in managing blood-glucose levels, particularly in preventing hypoglycemia and hyperglycemia, with existing glucose-responsive systems being suboptimal and not in clinical use.
Innovation Solution
Development of novel insulin analogues with a glucose-regulated molecular structure, featuring a diol-containing side chain in the B chain and a glucose-binding element attached to the A chain, allowing for a conformational switch between inactive and active states based on glucose concentration, enhancing receptor binding affinity at high glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional insulin therapies are used, then blood-glucose control is achieved, but hypoglycemia and hyperglycemia cannot be effectively prevented
Solution Approach 1:
The patent applies dynamics by creating an insulin analogue whose conformation and biological activity dynamically respond to glucose concentration changes. The molecule transitions between inactive and active conformations based on glucose binding, enabling automatic adjustment of insulin activity to match physiological needs and prevent harmful glucose level fluctuations.
Solution Approach 2:
The patent utilizes parameter changes by modifying the insulin molecule's conformational state in response to glucose concentration. The glucose-binding element induces conformational changes that alter the insulin's biological activity, creating a glucose-dependent activation mechanism that improves blood-glucose control reliability while preventing hypoglycemia and hyperglycemia.
2Adaptability or versatility
If existing glucose-responsive systems are developed, then glucose-dependent activation is achieved, but the systems are suboptimal and not suitable for clinical use
Solution Approach 1:
The patent applies segmentation by dividing the insulin molecule into distinct functional domains: an A-chain with glucose-binding elements and a B-chain with diol-containing side chains. This segmentation allows independent optimization of glucose-sensing and insulin-activity functions, achieving reliable glucose-dependent activation suitable for clinical use.
Solution Approach 2:
The patent creates a composite insulin analogue by combining modified A-chain and B-chain segments with specific chemical groups (glucose-binding elements and diol-containing side chains). This composite structure integrates glucose-sensing capability with insulin biological activity, producing a reliable glucose-responsive system with clinical applicability.
3Reliability
If insulin analogues with glucose-regulated conformation are designed, then receptor binding affinity at high glucose levels is enhanced, but molecular structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (glucose-binding elements at A-chain positions and diol-containing side chains at B-chain positions) into otherwise native insulin structures. This localized modification approach enhances receptor binding affinity through conformational changes while minimizing overall molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These insulin analogues provide improved glucose-dependent activation, reducing the risk of hypoglycemia while maintaining effective glucose control, offering enhanced pharmaceutical properties such as stability and pharmacokinetics.
Implementation Method 1
reversible covalent link between the diol and the boron atom
Data Source
AI summary
A two-chain insulin analogue is provided containing (a) a B chain modified by the addition of a C-terminal diol element in combination with (b) a glucose-binding element attached to the A chain at or near its N terminus, optionally linked to a D-amino acid. A “flipped” set of insulin analogues wherein the A chain is modified by addition of an N-terminal diol element whereas the glucose-binding element is attached at or near the C terminus of the B chain is also provided. Compositions comprising such insulin analogues are used in methods of treating a patient with diabetes mellitus.